Back to the main directory
EarningsReview / Equity
- Digital Workforce - Growth returning, with pivot towards profitability by Danske Bank Equity Research
- Spar Nord - Adding NII excitement to the fee machine by Danske Bank Equity Research
- ISS - ISS should deliver 5% margin in 2025 by Danske Bank Equity Research
- Aker Horizons - Buy/NOK 28 (29.50): Well-positioned for a counter-cyclical strategy by Nordea
- Fenix Outdoor - Buy/SEK 1,100 (1,200): Decent report in a challenging environment by Nordea
- Lumi Gruppen - Hold: Not out of the woods yet by Nordea
- Multiconsult - Buy/NOK 160 (170): Steady performance in a tougher market by Nordea
- Novo Nordisk - Buy/DKK 935 (915): Another guide hike and Wegovy relaunch on track by Nordea
- Sampo - Buy/EUR 54: Operational excellence and high capital returns by Nordea
- Sydbank - Buy/DKK 300 (278): Strong NII momentum to continue in Q4 2022 by Nordea
- AMSC ASA - Initiation of coverage - Maximising opportunity by DnB Markets
- Smartoptics (Buy, TP: NOK28.00) - Steady value creation by DnB Markets
- Aker Biomarine (Hold, TP: NOK40.00) - Q3 miss, 2022 guidance revised by DnB Markets
- YIT (Hold, TP: EUR2.60) - Still investing in growth despite weak outlook by DnB Markets
- Scorpio Tankers (Buy, TP: USD58.20) - Cash build potential by DnB Markets
- Bakkafrost (Hold, TP: NOK525.00) - Cautious into Q3e by DnB Markets
- Sparebanken Øst (Hold, TP: NOK52.00) - Margin tailwinds in challenging Q3 by DnB Markets
- Sampo Oyj (Buy, TP: EUR52.00) - Capital release remains firm by DnB Markets
- Arovella Therapeutics - Strategic refocus on iNKT platform by Edison Investment Research
- Datatec - The positives outweigh the negatives by Edison Investment Research
- Oryzon Genomics - Clinical ramp in Q3; several catalysts approaching by Edison Investment Research
- Sequana Medical - POSEIDON results de-risk alfapump programme by Edison Investment Research
- Indra - 3Q22 Results Review: Strong numbers, guidance confirmed; we reiterate Buy by JB Capital Markets
- Itaú BBA on Blau Farmacêutica: Soft as Expected; Hopeful for 4Q22 by Itau
- No One Saw It Coming by BNP Paribas Exane
- Novozymes - More confident about 2023 by Danske Bank Equity Research
- Harvia - Impressive margins – upgrade to Buy by Danske Bank Equity Research
- A.P. Moeller - Maersk - Hold: Continued uncertainty about Ocean's rates in 2023 by Nordea
- Biotage - Buy/SEK 235: Legacy business and FX counterbalance Scale Up by Nordea
- ISS - Hold: Strong Q3 growth, CMD targets next week are key by Nordea
- Mekonomen - Buy/SEK 140: Handling the situation well by Nordea
- Nobia - Hold: Too early to gather around the table by Nordea
- Raisio - Buy/EUR 2.40 (Hold): Returning to a profitable path by Nordea
- Sinch - Hold: Balance sheet risks over, but estimates risk persists by Nordea
- Vestas Wind Systems - Hold: If its ASP reflects inflation, peers may face problems by Nordea
- Novo Nordisk (Buy, TP: DKK930.00) - Another guidance increase by DnB Markets
- Hexagon Purus (Buy, TP: NOK22.00) - Growth story intact by DnB Markets
- Demant (Buy, TP: DKK260.00) - Unexpected guidance cut by DnB Markets
- Icelandic Salmon (Buy, TP: NOK195.00) - Solid Q3e coming up by DnB Markets
- Norwegian Air Shuttle (Buy, TP: NOK10.00) - October traffic statistics preview by DnB Markets
- Valaris (Buy, TP: USD90.00) - NAV support while waiting for cash flow by DnB Markets
- Nobia (Hold, TP: SEK19.00) - Q3 in line with profit warning by DnB Markets
- PhotoCure (Buy, TP: NOK140.00) - US BLC launch off to a good start by DnB Markets
- BioPharma Credit - A quality dividend play with FY22 yield of 12% by Edison Investment Research
- Foxtons Group - Strong markets and strategic initiatives shine by Edison Investment Research
- OSE Immunotherapeutics - OSE-127 Phase II study enrolment completed by Edison Investment Research
- BCP - (Tail)winds of change for capital are close; reiterating Buy by JB Capital Markets
- Century Pacific Food (CNPF PM) by HSBC
- Squeezed by BNP Paribas Exane
- Snapping back by BNP Paribas Exane